EGFR and non-small cell lung carcinoma: Several studies have demonstrated that patients with an exon 19 deletion experienced, on average, longer PFS and OS than those with an L858R mutation after first-line EGFR-TKI treatment for advanced non-small cell lung cancer [37, 38], indicating the clinical significance of the type of EGFR gene TKI-sensitive mutation.